Biotech Values

[DewDiligence]

FCSC—I will be back on June 22nd.

Do that if you like, but I don’t especially care if laViv gets FDA approval on June 22 (or any other date); the salient point is that laViv does not satsify an unmet medical need and is destined to be a commercial bust.

I had this kind of discussion with iHub posters who were wildly bullish about SOMX’s Silenor and DDSS’ Oleptro. These stocks were heavily pumped on iHub (as FCSC surely is now), the companies got FDA approval, the drugs are utterly inconsequential in the commercial marketplace, and the former pumpers are MiA. FCSC will follow the same script, IMO (unless the FDA doesn’t approve, in which case you will lose most of your money in short order).